You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Time is Your Ally

What are the risks in the 'wait and see' approach for patients with COPD who are not adequately treated on an ICS/LABA maintenance regimen.

COPD Exacerbations

In COPD patients who exacerbated in the previous year, >40% will experience a moderate/severe exacerbation over 12 months on dual maintenance therapy* 1

COPD lung function

Even a single exacerbation could lead to ~40% faster decline in lung function vs. no exacerbation^ 5

Identifying patients with COPD who are symptomatic and at risk of an exacerbation** despite treatment with an ICS/LABA regimen.

Patients with COPD who are symptomatic and at risk of an exacerbation** can be difficult to identify. 4 How can you uncover more when they tell you they "feel fine”?

Learn more about the burden of COPD in Ireland

Watch the video to hear from Professor Ross Morgan, Beaumont Hospital, Dublin, discuss the burden of COPD in Ireland.

Video player requires JavaScript enabled. You can download this video here:

How can Trelegy▼Ellipta (fluticasone furoate/umeclidinium/vilanterol) help?

Watch how TRELEGY Ellipta compared against an ICS/LABA in terms of exacerbation reduction, lung function and health-related quality of life.

^Post-hoc analysis of the 3-year TORCH study in patients with moderate or severe COPD. The primary end point did not reach statistical significance. Data shown compared patients with 0-1 moderate/severe exacerbations per annum vs 0 exacerbations per annum.

*Based on a 52-week, randomised, double-blind, non-inferiority trial comparing indacaterol/glycopyrronium (110/50 μg) once daily to fluticasone propionate/salmeterol (500/50 μg) twice daily in COPD patients with a history of at least one exacerbation in the previous year (for which they received treatment with systemic glucocorticoids, antibiotic agents, or both). IND/GLY showed non-inferiority and superiority to FP/SAL in reducing the annual rate of all COPD exacerbations.

LAMA/LABAs are indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. 1

**Defined as a worsening of symptoms, or has experienced an exacerbation treated with antibiotics or oral corticosteroid in the past 12 months.

†Retrospective analysis of annual rates of decline in FEV1 and FVC before and after a single moderate-to-severe exacerbation in patients with moderate to very severe COPD during the UPLIFT study. 2

††A retrospective cohort of newly diagnosed COPD patients (N=3199) identified in the Clinical Practice Research Datalink (CPRD). Maintenance therapy prescribed within the first 3 months of diagnosis and in the subsequent 3-month intervals for 24 months were analysed. 3


  1. Wedzicha J, et al N Engl J Med 2016; 374:2222-2234.
  2. Halpin DMG et al. Resp Med 2017; 128:85-91.
  3. Wurst KE, Punekar YS, Shukla A. PloS One 2014, 9: e105296.
  4. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD), 2020.
  5. Celli B et al. Am J Respir Crit Care Med 2008; 178:332–338

TRELEGY Ellipta was created in collaboration with


Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.